TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06072612: Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Sponsor: BriaCell Therapeutics Corporation · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 404 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$5,051,508

Rescue Site Savings

+$3,345,804

Unlock Full NCT06072612 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06072612 Rescue Dossier →